TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Photopic Monocular Distance Corrected VA (53 cm) at Day 120-180
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cumulative and Persistent Adverse Events as Defined in IS EN ISO 11979-7:2006, up to Day 120-180
Endpoint domain: Adverse events/effects
Primary endpoint: Photopic Contrast Sensitivity Without Glare at Day 120-180
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of ocular and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet expression of CD62P (P-selectin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fibrinogen binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects with on-treatment drug-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Pc colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Off-protocol Transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Recipient Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Recipient Cell Free Hemoglobin(CFH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Haptoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: size of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of response rate better than very good partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measles vaccination coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of acid-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Bone Marrow Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cortisol Awakening Response Level (nmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dosimetric gain on organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameter (Cmax) of F/TAF in the systemic compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p24 antigen production in cervicovaginal and rectal tissue infected with HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HIV activity in cervicovaginal and rectal fluid (TZM-bl inhibition measured as mean percent reduction compared to control)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Proliferation (Percentage of Ki-67 Positive Cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Discontinuing Treatment Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Who Were MR Scan-Related ImageReady System Complication-Free
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participant Whose the Average RV Shocking Impedance is >200 Ohm 1 Month Post Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participant That Have an Increase in Average RV Pacing Thresholds > 0.5V From Pre-MR Scan to MRI Visit + 1 Month Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participant That Have the Average RV Sensed Amplitude at the MRI + 1 Month Visit Remains < 5.0 mV or Less Than 50% of the Pre-MR Scan Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Summary of Diabetes Self-Care Activities measure (SDSCA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short form of the sense of coherence questionnaire (SOC-13)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intestinal gas evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Volume of the hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortical thickness of the hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Microstructural integrity of the hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cycloplegic autorefraction measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC VA3.1 Pain Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma concentrations of BAIBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: decrease waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants who complete the study protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportions of patients achieving remission rate during induction therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival (intensification)
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival following consolidation
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients With Plasma HIV RNA <50 Copies/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Annualized Bleeding Rate (ABR) for All Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in worst daily pain severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication free at 1 year post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 year progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of CD4+ T-cells in the Lamina Propria/mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wound culture test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total sleep time at night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Amplitude of the sleep wake rhythm
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Penile Doppler ultrasonography findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale - Session III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Clavien-Dindo Classification
Endpoint domain: Adverse events/effects
Primary endpoint: Abundances of microorganisms in the cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vitamin B12 biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hSBA Seroresponse in Healthy Children 2 to 5 Years of Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hSBA Seroresponse in Healthy Children 6 to 10 Years of Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence/Severity of Palmar-plantar Erythrodysesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Complete or near Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Arepanrix
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of Arepanrix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean oxygen saturation at 30 minutes postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of workers' lost-time claims
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Infarct size (percentage of myocardium at risk)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mood Outcome Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cost-utility of minimalist TAVR compared to SAVR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from Pressure Pain Thresholds (PPT) at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from State-Trait Anxiety Inventory subscale (STAI-E) at 24 hours
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of inflammatory infiltrate, ischemia, infarction in the myocardial tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular ejection fraction (Echo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Connor Davidson Resilience Scale (CD-RISC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle strength assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in working memory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Electrocardiogram (ECG) Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants who receive an HIV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants with HIV RNA <400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants who complete all HIV retest visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pulmonary function (FEV1, FVC, TLC, DLco)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative thrombin generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Skin temperature changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Active Chest Flexibility test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Reach Flexibility test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance of semirecumbent position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urticaria activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological response of the primary tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Brain functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of pre-cancer abnormalities of the cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fugl-Meyer Upper-Extremity Scale (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in abdominal girth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of the episode of care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of interventions to attain resolution of stenosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pre-hospital care profile of RTI victims
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Experiences of renal disease and renal replacement therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of PF-04523655
Endpoint domain: Adverse events/effects
Primary endpoint: changes from baseline HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Physical and/or Sexual IPV
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Prevalence of Physical and/or Sexual IPV
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate after one year of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ascending Colon Emptying Half-time (AC t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety of AG-024322
Endpoint domain: Adverse events/effects
Primary endpoint: AG-024322 dose determination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood concentrations of AG-024322
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: global volume of lymphoceles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Prevalence of HAE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Feasibility of recruitment of dyads for the WLSCC Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of agreeing to participate in the WLSCC study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fidelity to the intervention protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in body temperature (Degree Celsius)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in heart beat (beats/minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in respiratory frequency (inspiration/minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in full blood Counts (number of cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tumor response after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical lab tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until surgery/Time until discharge (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Swelling as measured by point of largest swollen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient reported pain as measured on VAS
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: renal regional oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients who die within one year
Endpoint domain: Mortality/survival
Primary endpoint: Cancer mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Non-cancer mortality
Endpoint domain: Mortality/survival
Primary endpoint: Morphometric evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: movement strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Haematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Erythema
Endpoint domain: Adverse events/effects
Primary endpoint: Score on the MADRS depression rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Genes predisposing to drug induced nephrotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of clinic attenders under 5 years diagnosed with anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Memory antibody response to Neisseria meningitidis serogroup C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in CYP2D6 and CYP3A4 phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: species-level molecular operational taxonomic units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bishop Score After 24 Hours of Maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Concordance (PPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Asthma Control to 3 Month Asthma Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tube exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Physiological change of physician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty in elderly patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grading system for esophageal varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Height (Amplitude) of Multifocal ERG Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Response (Implicit Time) of Multifocal ERG Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RV diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with child health or development risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and follicular fluid oxidative stress biomarkers levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Able to Use the ORCAM Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinue Injectable Study Product for Reasons of Toxicity, Tolerability, or Acceptability
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Drug Levels of GSK1265744
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of composite of mortality or major postoperative morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Unprotected vaginal or anal intercourse
Endpoint domain: Adverse events/effects
Primary endpoint: Sharing of injection drug works
Endpoint domain: Adverse events/effects
Primary endpoint: AUCt of ambroxol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ambroxol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subject-assessed itching and burning/stinging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in physician-assessed erythema scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in physician-assessed dryness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in physician-assessed peeling scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite outcome of deep vein thrombosis, pulmonary embolus, and death due to TED
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of FH patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value (NPV) of the CCE2 for large polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: functional vascular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Composite of Recurrent VT or VT storm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of active inflammatory lesions in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 - Year Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: cost utility ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Platelet response to different agonists
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Granular Delta content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Measurement of ATP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Vancouver Scar Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes